Targeting the cancer epigenome for therapy

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• Over 50% of human cancers harbor mutations in chromatin organization enzymes.
• Tumor cells exploit epigenetic processes for chemotherapy resistance and immune evasion.

Purpose of the Study:

• To highlight the therapeutic potential of targeting the epigenome in cancer treatment.
• To discuss the role of epigenetic drugs in overcoming treatment resistance.

Main Methods:

• Review of next-generation sequencing data on cancer mutations.
• Analysis of epigenetic mechanisms in tumor progression and immune evasion.
• Examination of current and emerging epigenetic drug therapies.

Main Results:

• Epigenetic alterations are prevalent in human cancers.
• Epigenetic drugs, including those targeting DNA methylation and histone modifications, are increasingly important in cancer therapy.
• Combination therapies involving epigenetic drugs show future promise.

Conclusions:

• Targeting the epigenome represents a significant advancement in cancer treatment.
• Epigenetic drugs act broadly, potentially simplifying personalized medicine approaches.
• The future of cancer therapy will likely involve successful combinations of epigenetic drugs with other treatments.